| Mutations of the BRAF gene in human cancer H Davies, GR Bignell, C Cox, P Stephens, S Edkins, S Clegg, J Teague, ... Nature 417 (6892), 949-954, 2002 | 12670 | 2002 |
| The landscape of cancer genes and mutational processes in breast cancer PJ Stephens, PS Tarpey, H Davies, P Van Loo, C Greenman, DC Wedge, ... Nature 486 (7403), 400-404, 2012 | 1910 | 2012 |
| A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B … VA Miller, P O'connor, C Soh, F Kabbinavar Journal of Clinical Oncology 27 (18_suppl), LBA8002-LBA8002, 2009 | 289 | 2009 |
| Whole exome sequencing of adenoid cystic carcinoma PJ Stephens, HR Davies, Y Mitani, P Van Loo, A Shlien, PS Tarpey, ... The Journal of clinical investigation 123 (7), 2965-2968, 2013 | 284 | 2013 |
| Analytical validation of a hybrid capture–based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA TA Clark, JH Chung, M Kennedy, JD Hughes, N Chennagiri, DS Lieber, ... The Journal of Molecular Diagnostics 20 (5), 686-702, 2018 | 214 | 2018 |
| A survey of homozygous deletions in human cancer genomes C Cox, G Bignell, C Greenman, A Stabenau, W Warren, P Stephens, ... Proceedings of the National Academy of Sciences 102 (12), 4542-4547, 2005 | 119 | 2005 |
| Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations K Wang, JS Russell, JD McDermott, JA Elvin, D Khaira, A Johnson, ... Clinical cancer research 22 (24), 6061-6068, 2016 | 111 | 2016 |
| Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses J Wheler, D Hong, SG Swisher, G Falchook, AM Tsimberidou, T Helgason, ... Oncotarget 4 (6), 890, 2013 | 56 | 2013 |
| Constitutional translocation breakpoint mapping by genome-wide paired-end sequencing identifies HACE1 as a putative Wilms tumour susceptibility gene I Slade, P Stephens, J Douglas, K Barker, L Stebbings, F Abbaszadeh, ... Journal of medical genetics 47 (5), 342-347, 2010 | 54 | 2010 |
| Erlotinib in lung cancer. C Nabhan, JD Bitran The New England journal of medicine 353 (16), 1739-41; author reply 1739, 2005 | 34 | 2005 |
| MA03. 05 BRAF Mutations Are Associated with Increased Benefit from PD1/PDL1 Blockade Compared with Other Oncogenic Drivers in Non-Small Cell Lung Cancer M Negrao, F Skoulidis, M Montesion, K Schulze, I Bara, V Shen, S Hu, ... Journal of Thoracic Oncology 14 (10), S257-S258, 2019 | 3 | 2019 |
| Memorial Sloan-Kettering Cancer Center VA Miller, P O'Connor, C Soh, F Kabbinavar, ATLAS Investigators New York, NY, 0 | 2 | |
| A novel PI3K/Akt-pathway activation biomarker using comprehensive genomic profiling (CGP) for clinical trial assay Y He, M Wongchenko, J Skoletsky, C Burns, Y Li, P Maness, D Kim, ... Cancer Research 78 (13_Supplement), 2582-2582, 2018 | | 2018 |
| A US-based prospective, multi-center, non-interventional study of the role of comprehensive genomic profiling in the clinic. NA Palma, Z Chalmers, Y Li, M Bailey, JS Ross, S Balasubramanian, ... Journal of Clinical Oncology 33 (15_suppl), e22183-e22183, 2015 | | 2015 |
| European Society for Medical Oncology and the Japanese Society of Medical Oncology F Lethimonnier, Y Levy, C Turnbull, S Piscuoglio, CKY Ng, B Weigelt, ... | | |
